Status:

COMPLETED

Tissue Expansion in Breast Reconstruction Without Drains

Lead Sponsor:

Cedars-Sinai Medical Center

Collaborating Sponsors:

Tiger Biosciences, LLC.

Conditions:

Breast Cancer

Hereditary Breast and Ovarian Cancer Syndrome

Eligibility:

FEMALE

21+ years

Brief Summary

The primary objective of this small feasibility pilot study is to demonstrate that implant-based breast reconstruction (after treatment for cancer) can successfully be performed without prolonged drai...

Detailed Description

Patients electing to have staged, implant-based, bilateral breast reconstruction at the time of mastectomy (for either cancer or cancer prevention) will undergo a standardized subpectoral tissue expan...

Eligibility Criteria

Inclusion

  • Patients undergoing bilateral breast reconstruction following mastectomy (performed to treat stage I-III breast cancer or for prevention of breast cancer).
  • Non-smokers
  • BMI less than 31
  • No other significant surgical risk factors that make elective use of implants dangerous (e.g., presence of a pacemaker, frail health, dependence on blood thinners, uncontrolled diabetes, bleeding tendencies, autoimmune disorders, immune compromise)

Exclusion

  • Unilateral mastectomy patients
  • Current smokers
  • Those with bleeding dyscrasias or clotting disorders
  • Those who have had or will have a full axillary lymph node dissection
  • Cases where there is an unusually high degree of bleeding intra-operatively (more than 150 cc)
  • Those with a BMI greater than 30
  • Those with history of prior breast surgery (aside from lumpectomy or needle biopsy)
  • Those with a history of prior breast radiation
  • Those with stage IV or unresectable breast cancer
  • Significant surgical risk factors that make elective use of implants dangerous (e.g., presence of a pacemaker, frail health, dependence on blood thinners, uncontrolled diabetes, bleeding tendencies, autoimmune disorders, immune compromise)

Key Trial Info

Start Date :

February 25 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 2 2020

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03784859

Start Date

February 25 2019

End Date

October 2 2020

Last Update

October 6 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048